The Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block in Patients Undergoing Primary Total Hip Arthoplasty:
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Ropivacaine, Physiological saline.
- Who it may be relevant to
- Registry conditions: Prospective, Randomized, Double-blind. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block in Patients Undergoing Primary Total Hip Arthoplasty: a Prospective, Double-blinded, Randomized Controlled Trial
Overview
The aim of this study is to investigate the analgesic efficacy of the pericapsular nerve group (PENG) block during the implantation of hip endoprostheses. The study is designed as a prospective randomized double-blind study and the study participants were randomized into 2 arms and either 20 ml ropivacaine 0.5% (verum group) or 20 ml physiological saline solution (placebo group) will be applied.
Interventions
- Drug Ropivacaine
PENG block with ropivacaine - Other Physiological saline
Placebo control
Primary outcome measures
- Rate of postoperative opioid administration [Time frame: 60 minutes after arrival in the recovery room]
Secondary outcome measures (4)
- Quantity of total opioid consumption [Time frame: until the evening of the second postoperative day]
- Intensity of postoperative pain [Time frame: until the evening of the second postoperative day]
- Intensity of postoperative nausea and vomiting [Time frame: until the evening of the second postoperative day]
- Postoperative recovery [Time frame: until the evening of the second postoperative day]
Eligibility criteria
Inclusion criteria
- planned cementless hip TEP operation for primary coxarthrosis via minimally invasive anterolateral approach using the identical implant system (Taperloc stem, Plamafit cup)
- Patient capable of giving consent
- Informed consent has been obtained
- age > 18 years
Exclusion criteria
- Refusal to participate in the study
- Regular use of opioids
- Known chronic pain symptoms
- Infections in the area of the puncture site
- Presence of a contraindication to ropivacaine
- Presence of a contraindication to metamizole
- Presence of a contraindication to postoperative analgesia with diclofenac
- Secondary forms of osteoarthritis with deformities (i.e. high-grade dysplasia, secondary conditions after trauma, secondary conditions after childtrauma, secondary conditions after childhood hip joint diseases
- Spinopelvic dysbalance, spinal canal stenosis
- Previous operations on the hip/pelvis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Germany · 1 center
- Diakonie-Klinikum Stuttgart — Stuttgart
Identifiers
NCT: NCT06557044 · Diak 001/2024